In ccRCC, it has been proposed that cytotoxic T cell activation and consequent response to immunotherapy are probably impaired by enhanced IL-6/JAK/STAT3, IFNα, IFNγ signaling routes and RIPK2-mediated signaling [234,235]. This evidence concerns the gene IL6 and nonpapillary renal cell carcinoma.